Earnings Announcement Next Earnings date is expected on 08/11/2022
Last Price$2.32Cboe Real-Time Last Sale as of 12:34PM ET 8/08/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.10(4.34%)
Bid (Size)$2.31 (3,150)
Ask (Size)$2.32 (1,001)
Day Low / High$2.32 - 2.54
Volume1.8 M

View Biotechnology IndustryPeer Comparison as of 08/08/2022


Geron Corp ( NASDAQ )

Price: $2.32
Change: -0.10 (4.34%)
Volume: 1.8 M
12:34PM ET 8/08/2022

Anavex Life Sciences Corp ( NASDAQ )

Price: $11.43
Change: -0.23 (1.97%)
Volume: 346.9 K
12:35PM ET 8/08/2022

Replimune Group Inc ( NASDAQ )

Price: $19.90
Change: -0.60 (2.93%)
Volume: 38.2 K
12:29PM ET 8/08/2022

Rocket Pharmaceuticals Inc ( NASDAQ )

Price: $15.49
Change: -0.07 (0.45%)
Volume: 274.2 K
12:35PM ET 8/08/2022

Rhythm Pharmaceuticals Inc ( NASDAQ )

Price: $21.83
Change: +1.59 (7.86%)
Volume: 1.5 M
12:35PM ET 8/08/2022

Read more news Recent News

--B. Riley Resumes Geron at Buy with $4 Price Target, Says Thesis Hinges on Potential Success of Imetelstat
9:57AM ET 7/28/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Geron Secures Additional $50 Million in Loan Capacity Through End of 2024
4:39PM ET 6/30/2022 MT Newswires

Geron (GERN) late Thursday said lenders Hercules Capital (HTGC) and Silicon Valley Bank have agreed to a $50 million increase to the biopharmaceutical...

Geron Names Faye Feller Chief Medical Officer
4:28PM ET 6/15/2022 MT Newswires

Geron (GERN) said late Wednesday it named Faye Feller chief medical officer, effective July 9. Feller succeeds Aleksandra Rizo, who will transition to the...

--Needham Trims Geron's Price Target to $2 From $3, Buy Rating Kept
11:14AM ET 5/10/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

View all Commentary and Analysis

Geron: Waiting For Godot
2:55PM ET 7/15/2022 Seeking Alpha

VERU's Shares Jump on Successful COVID-19 Study Results
10:44AM ET 7/08/2022 Zacks

VERU gains on the success of its late stage study evaluating the efficacy and safety of oral...

Geron (GERN) presents at H.C. Wainwright Global Investment Conference - Slideshow
2:54PM ET 5/24/2022 Seeking Alpha

Geron Corporation 2022 Q1 - Results - Earnings Call Presentation
11:07AM ET 5/10/2022 Seeking Alpha

Company Profile

Business DescriptionGeron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA. View company web site for more details
Address919 East Hillsdale Boulevard
Foster City, California 94404
Number of Employees17
Recent SEC Filing07/12/20223
Chairman, President & Chief Executive OfficerJohn A. Scarlett
Chief Operating Officer & Executive Vice PresidentAndrew J. Grethlein
Chief Financial Officer, Treasurer & Executive VPOlivia K. Bloom
Chief Medical Officer & Executive Vice PresidentFaye Feller

Company Highlights

Price Open$2.46
Previous Close$2.42
52 Week Range$0.99 - 2.67
Market Capitalization$873.8 M
Shares Outstanding377.4 M
SectorHealth Technology
Next Earnings Announcement08/11/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.36
Beta vs. S&P 500N/A
Revenue$1.1 M
Net Profit Margin-8,584.92%
Return on Equity-85.84%

Analyst Ratings as of 07/27/2022

Consensus RecommendationConsensus Icon
Powered by Factset